Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Raymond

Showing results (431-440 of 1,063) with videos related to

Pageof 107
Sort By:
Open Forum Infectious Diseases|August 14, 2024
Diverse Clinical Manifestations and Challenges of Mucormycosis: Insights From Serial CasesMarisa C Nielsen, Filipe M Cerqueira, Sri Bharathi Kavuri, et al.
Clinical Lung Cancer|July 16, 2020
Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA AnalysisKaren L Reckamp, Tejas Patil, Kedar Kirtane, et al.
Journal of Genetic Counseling|August 26, 2017
Physician Experiences and Understanding of Genomic Sequencing in OncologyCaroline M Weipert, Kerry A Ryan, Jessica N Everett, et al.
Plos One|July 16, 2015
Adolescents' Neural Processing of Risky Decisions: Effects of Sex and Behavioral DisinhibitionThomas J Crowley, Manish S Dalwani, Susan K Mikulich-Gilbertson, et al.
Gut|August 1, 1996
Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patientsP Ruszniewski, M Ducreux, J A Chayvialle, et al.
The American Journal of Gastroenterology|November 30, 2000
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumorsM Ducreux, P Ruszniewski, J A Chayvialle, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenograftsR A Newman, J Yang, M Raymond, et al.
Molecular Genetics and Metabolism|June 18, 2020
Laboratory monitoring of patients with hereditary tyrosinemia type IMatthew J Schultz, Brian C Netzel, Rani H Singh, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2008
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitorsClifford D Jones, David M Andrews, Andrew J Barker, et al.
Personalized Medicine|October 20, 2015
Illustrative case studies in the return of exome and genome sequencing resultsLaura M Amendola, Denise Lautenbach, Sarah Scollon, et al.
Pageof 107

Showing results (431-440 of 1,063) with videos related to

Sort By:
Pageof 107
Open Forum Infectious Diseases|August 14, 2024
Diverse Clinical Manifestations and Challenges of Mucormycosis: Insights From Serial CasesMarisa C Nielsen, Filipe M Cerqueira, Sri Bharathi Kavuri, et al.
Clinical Lung Cancer|July 16, 2020
Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA AnalysisKaren L Reckamp, Tejas Patil, Kedar Kirtane, et al.
Journal of Genetic Counseling|August 26, 2017
Physician Experiences and Understanding of Genomic Sequencing in OncologyCaroline M Weipert, Kerry A Ryan, Jessica N Everett, et al.
Plos One|July 16, 2015
Adolescents' Neural Processing of Risky Decisions: Effects of Sex and Behavioral DisinhibitionThomas J Crowley, Manish S Dalwani, Susan K Mikulich-Gilbertson, et al.
Gut|August 1, 1996
Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patientsP Ruszniewski, M Ducreux, J A Chayvialle, et al.
The American Journal of Gastroenterology|November 30, 2000
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumorsM Ducreux, P Ruszniewski, J A Chayvialle, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2001
Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenograftsR A Newman, J Yang, M Raymond, et al.
Molecular Genetics and Metabolism|June 18, 2020
Laboratory monitoring of patients with hereditary tyrosinemia type IMatthew J Schultz, Brian C Netzel, Rani H Singh, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2008
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitorsClifford D Jones, David M Andrews, Andrew J Barker, et al.
Personalized Medicine|October 20, 2015
Illustrative case studies in the return of exome and genome sequencing resultsLaura M Amendola, Denise Lautenbach, Sarah Scollon, et al.
Pageof 107